First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer

被引：0
|
作者：
Thomas J. W. Klein Nulent
Robert J. J. van Es
Stefan M. Willems
Arthur. J. A. T. Braat
Lot A. Devriese
Remco de Bree
Bart de Keizer
机构：
[1] University Medical Center Utrecht,Department of Head and Neck Surgical Oncology
[2] University Medical Center Utrecht,Department of Oral and Maxillofacial Surgery
[3] University Medical Center Utrecht,Department of Pathology
[4] University Medical Center Groningen,Department of Pathology and Medical Biology
[5] University Medical Center Utrecht,Department of Radiology and Nuclear Medicine
[6] University Medical Center Utrecht,Department of Medical Oncology
来源：
EJNMMI Research | / 11卷
关键词：
Lutetium; Positron-emission tomography; Radionuclide; Adenoid cystic carcinoma; Salivary gland cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617
    Ferdinandus, Justin
    Eppard, Elisabeth
    Gaertner, Florian C.
    Kuerpig, Stefan
    Fimmers, Rolf
    Yordanova, Anna
    Hauser, Stefan
    Feldmann, Georg
    Essler, Markus
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (02) : 312 - 319
  • [22] Hematotoxicity after radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Zimbelmann, Stefanie
    Eppard, Elisabeth
    Hauser, Stefan
    Kuerpig, Stefan
    Yordanova, Anna
    Essler, Markus
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [23] Challenges with 177Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice
    Jadvar, Hossein
    Iravani, Amir
    Bodei, Lisa
    Calais, Jeremie
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (12) : 1851 - 1854
  • [24] Administration of 177Lu-PSMA-617 as Compared to 177Lu-Dotatate
    Patel, P.
    McCall, K.
    MEDICAL PHYSICS, 2022, 49 (06) : E811 - E812
  • [25] Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
    Sun, Michael
    Niaz, Muhammad O.
    Nelson, Adlai
    Skafida, Myrto
    Niaz, Muhammad J.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (06)
  • [26] 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
    Fadi Khreish
    Niklas Ebert
    Martin Ries
    Stephan Maus
    Florian Rosar
    Hendrik Bohnenberger
    Tobias Stemler
    Matthias Saar
    Mark Bartholomä
    Samer Ezziddin
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 721 - 728
  • [27] Dose Escalation Experience with 177Lu-PSMA-617
    Rathke, H.
    Giesel, F. L.
    Flechsig, P.
    Kopka, K.
    Mier, W.
    Hohenfellner, M.
    Haberkorn, U.
    Kratochwil, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S280 - S281
  • [28] 177Lu-PSMA-617 vs Cabazitaxel in MCRPC
    不详
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (04) : 13N - 13N
  • [29] 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
    Khreish, Fadi
    Ebert, Niklas
    Ries, Martin
    Maus, Stephan
    Rosar, Florian
    Bohnenberger, Hendrik
    Stemler, Tobias
    Saar, Matthias
    Bartholomae, Mark
    Ezziddin, Samer
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (03) : 721 - 728
  • [30] Predictors of better response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Ferdinandus, Justin
    Eppard, Elisabeth
    Kuerpig, Stefan
    Gaertner, Florian
    Fimmers, Rolf
    Hauser, Stefan
    Essler, Markus
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
12345